drugset
drugset / Trial / NCT03936270

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

NCT03936270 ↗

Phase 2 Completed 43 enrolled Latin American Cooperative Oncology Group Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate 12 weeks progression-free survival (PFS) rate of Palbociclib plus Letrozole in ER/PR positive endometrioid or high-grade serous ovarian cancer who have disease progression on second-line chemotherapy.

Timeline

Start
2020-03-05
Primary completion
2022-01-18
Completion
2023-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral
Subject Palbociclib Small molecule 125 mg Oral

Indications

ovarian cancer